Core Viewpoint - Glucotrack, Inc. has received three patents for its continuous blood glucose monitoring (CBGM) platform, enhancing its competitive position and intellectual property protection as it moves towards commercialization of its fully implantable system [1][4]. Patent Details - The patents cover essential technologies in Glucotrack's CBGM system, including proprietary sensor chemistry, intravascular lead design, and low-power electronics [2]. - The patents issued are US 12,453,494, US 12,458,257, and US 12,458,258, which focus on improving glucose measurement methods and sensor design [9]. Product Features - Glucotrack's CBGM is designed for long-term implantation, with a sensor longevity of up to three years and no wearable components, providing a more convenient glucose monitoring solution [4][6]. - The system measures glucose directly from blood, aiming to deliver real-time readings without the lag associated with traditional interstitial fluid measurements [4]. Strategic Importance - Securing these patents is a significant milestone for Glucotrack, as it establishes competitive barriers and strengthens the company's position in the diabetes management market [4].

Core Insights - Apyx Medical Corporation is participating in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026 [1] Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion and the AYON Body Contouring System [2] - The company utilizes Helium Plasma Platform Technology, which provides controlled heat to tissue, enhancing surgical outcomes [2] - Renuvion and J-Plasma are supported by over 90 clinical documents, demonstrating their effectiveness in both cosmetic and hospital surgical markets [2] - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple functionalities, including fat removal and tissue contraction, into a single platform [2] - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [2]

Core Insights - Cortigent is a leading developer of brain implant devices utilizing precision neurostimulation technology, and it is the only company with FDA approval for a device providing artificial vision for the profoundly blind [1][7] - The Orion Visual Cortical Prosthesis System, developed by Cortigent, aims to deliver meaningful visual perception to blind individuals and has shown promising results in a 6-year Early Feasibility Study [1][3] - The company is also working on a new medical device to enhance recovery of arm and hand motion in patients with paralysis due to stroke [1][7] Study Results - The Early Feasibility Study involved six subjects implanted between January 2018 and January 2019, concluding in March 2025 [6] - All subjects demonstrated improvement in visual function tests with the Orion system activated, achieving positive or mild positive scores on the Functional Low-vision Observer Rated Assessment (FLORA) [6] - The study reported a loss of functionality in fewer than 4% of electrodes, with only one serious adverse event (a seizure) occurring early in the study [6] Future Plans - Cortigent plans to conduct a larger pivotal clinical trial to seek marketing approval for the Orion system, pending discussions with the U.S. Food and Drug Administration [3][5] - The company aims to advance the Orion cortical stimulation system in 2026, collaborating with leading experts and regulatory bodies [5] Technology Overview - The Orion system features a wirelessly powered implantable pulse generator connected to an array of 60 micro-electrodes for implantation on the visual cortex of blind patients [2] - A small processing unit worn on the belt converts real-time video from specialized glasses into wireless commands to stimulate neurons, creating visual perception through phosphenes [2] Company Background - Cortigent is a wholly-owned subsidiary of Vivani Medical, Inc., which is focused on developing advanced medical devices through its proprietary neurostimulation technology platform [1][7] - The Orion system has received FDA Breakthrough Device designation and is protected by an extensive intellectual property estate [7]

Company Overview - West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services, supporting both established and emerging drug developers [4] - The company has over 10,000 team members across 50 sites, including 25 manufacturing facilities worldwide, delivering over 41 billion components and devices each year [4] - In fiscal year 2024, West generated $2.89 billion in net sales and is traded on the New York Stock Exchange (NYSE: WST) [5] Upcoming Financial Results - West Pharmaceutical Services will release its fourth-quarter and full-year 2025 financial results before the market opens on February 12, 2026 [1] - A conference call to discuss the results and business expectations will take place at 8:00 a.m. Eastern Time on the same day [1] Investor Engagement - A live webcast of the conference call will be available, and participants must register in advance to ask questions [2] - A slide presentation will be accessible in the Investors section of the company's website on the day of the call, with a replay available for approximately 90 days after the event [3]

Invenio previously announced that the FDA granted Breakthrough Device Designation for NIO Lung Cancer Reveal, an investigational AI image-analysis module designed to assist physicians in evaluating images from fresh bronchoscopic lung forceps biopsy specimens acquired with the NIO Laser Imaging System. The investigational module is not cleared or approved for clinical use in the United States. With its expanded Board, Invenio remains focused on commercialization and broadening access to its platform to supp ...

Core Viewpoint - Boston Scientific Corporation (BSX) is a global medical device company with a market cap of $138.8 billion, focusing on innovative technologies across various medical specialties, including cardiovascular and gastrointestinal conditions [1] Financial Performance - BSX shares have underperformed the broader market, decreasing 8.3% over the past 52 weeks, while the S&P 500 Index gained 15% [2] - Year-to-date, BSX shares have declined 1.6%, compared to the S&P 500's 1.9% return [2] - The company's stock also lagged behind the State Street Health Care Select Sector SPDR ETF's 5.3% rise over the past year [3] Recent Developments - On October 22, 2025, BSX shares rose nearly 4% after reporting Q3 2025 adjusted EPS of $0.75 and revenue of $5.07 billion, exceeding expectations [4] - The company raised its 2025 adjusted EPS forecast to a range of $3.02 - $3.04 and guided Q4 adjusted EPS of $0.77 - $0.79, above consensus estimates [4] - Strong demand for heart devices, particularly a 23.1% increase in electrophysiology sales driven by the Watchman and Farapulse systems, contributed to investor optimism [4] Analyst Ratings and Forecasts - Analysts expect BSX's adjusted EPS to grow 21.1% year-over-year to $3.04 for the fiscal year ending December 2025 [5] - The company has a promising earnings surprise history, beating consensus estimates in the last four quarters [5] - Among 31 analysts covering BSX, the consensus rating is a "Strong Buy," with 26 "Strong Buy" ratings, three "Moderate Buys," and two "Holds" [5] Price Targets - Bernstein analyst Lee Hambright maintained a "Buy" rating on BSX with a price target of $130 [6] - The mean price target of $125.53 indicates a 33.8% premium to BSX's current price levels [6] - The highest price target of $140 suggests a potential upside of 49.3% [6]

Core Viewpoint - Globus Medical, Inc. is a prominent player in the medical device industry, focusing on musculoskeletal disorders and competing with major companies like Medtronic and Stryker [1] Stock Performance - Over the past month, GMED's stock price has increased by approximately 4.44%, indicating strong investor confidence and positive market sentiment [2] - In the last 10 days, the stock experienced a slight decline of about 0.70%, which may present a buying opportunity for investors [2] Growth Potential - GMED's stock has a growth potential of 9.14%, appealing to growth-oriented investors [3] - The company's financial health is highlighted by a Piotroski Score of 8, indicating solid fundamentals in profitability, liquidity, and operational efficiency [3] Analyst Insights - Analysts have set a target price of $100.20 for GMED, suggesting potential for higher valuations [4] - The stock recently touched a local minimum, which may signal a potential rebound, encouraging investors to consider entering a position [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline on February 9, 2026 [1] Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lead plaintiff must file a motion with the Court by February 9, 2026, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4] Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5] - It is claimed that Integer overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5] - The lawsuit asserts that these misrepresentations led to investor damages when the true details became public [5]

Steel Partners has made an offer to buy a majority stake in InMode, which makes devices for minimally invasive body treatments, according to sources https://t.co/4E8IA0rTdf ...

Q4 2025 Earnings Presentation Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer January 28th, 2026 CONMED Vision Empower healthcare providers worldwide to deliver exceptional outcomes for patients. This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in t ...